Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
38.15
Nov 20 • 3:59 PM ET Dollar change-1.62 Percentage change(-4.07%)
Aftermarket Close
38.15
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Category
US Equities - Industry Sector
Sponsor
Virtus ETF Solutions
Fund Family
Index
LifeSci Biotechnology Clinical Trials In...
Index Weighting
Active/Passive
Expense
0.65%
Inverse/Leveraged
IPO
Dec 17, 2014
Asset Type
Equities (Stocks)
ETF Type
Bond Type
Average Maturity
Commodity Type
Quant Type
ESG Type
Dividend Type
Structure Type
Growth/Value
Market Cap
Option/Short
Yes / No
Tags
Tags
Tags
Tags
Tags
Tags
-
Tags
-
Sector/Theme
Region
SMA20
-9.84%
SMA50
-12.76%
SMA200
-16.48%
Return% 1Y
19.83%
Return% 3Y
30.56%
Return% 5Y
-2.04%
Return% 10Y
Return% SI
Flows% 1M
-16.55%
Flows% 3M
-16.55%
Flows% YTD
-5.00%
Flows% 1Y
Flows% 3Y
Flows% 5Y
Trades
Total Holdings
130
AUM
31.81M
NAV/sh
52W High
56.18 -32.09%
52W Low
33.20 14.91%
Volatility
4.20% 3.81%
ATR (14)
1.65
RSI (14)
34.32
Beta
0.96
Rel Volume
1.57
Avg Volume
34.05K
Volume
53,437
Perf Week
-10.29%
Perf Month
-9.45%
Perf Quarter
-29.52%
Perf Half Y
-10.67%
Perf YTD
-1.06%
Perf Year
13.34%
Perf 3Y
97.75%
Perf 5Y
-11.48%
Perf 10Y
76.38%
Prev Close
39.77
Price
38.15
Change %
-4.07%
Virtus LifeSci Biotech Clinical Trials ETF seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index. Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.